Status:
COMPLETED
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
Lead Sponsor:
University of Vermont
Conditions:
Breast Cancer
Angiogenesis
Eligibility:
FEMALE
18-95 years
Phase:
EARLY_PHASE1
Brief Summary
Changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. One source of these proteins is the circulating plate...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven breast cancer
- Pre or post-menopausal
- Age \>18
- Completed adjuvant non-hormonal therapy \>30 days prior to initiation of study (surgery and/or chemotherapy and/or radiation therapy)
- Platelet count and hemoglobin within normal ranges for local lab within 30 days of initiation of study therapy
- Receiving tamoxifen therapy for at least 90 days prior to initiation of study therapy, and is expected to continue that therapy for the duration of the study (75 days)
Exclusion
- Chemotherapy, radiation therapy or surgery within 30 days of study therapy
- Current use of aspirin, anti-platelet or anti-coagulation agents on a continuous basis
- Prior history of gastrointestinal or central nervous system bleeding, or documented or self-reported blood in stools or bright red blood per rectum
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00727948
Start Date
July 1 2008
End Date
December 1 2012
Last Update
September 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05401